JPMorgan Healthcare Conference
|
|
- Marilynn Byrd
- 5 years ago
- Views:
Transcription
1 Pioneering a first-in-class, oral immuno-oncology therapy JPMorgan Healthcare Conference January 2018
2 Forward-Looking Statements This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of Such forward-looking statements include those regarding the company s expectations about: the therapeutic potential of PI3K-gamma selective inhibition and IPI-549, alone and in combination with immune checkpoint inhibitors, including Opdivo ; clinical trial plans regarding IPI-549, including enrollment projections and timing for trial expansion; the timing and type of plans to report clinical and translational data of IPI-549; patent protection for IPI-549; the market sizes and commercial opportunity for IPI-549; 2017 year-end cash and investments balance and 2018 financial guidance as of January 8, 2018; and the company s ability to execute on its strategic plans. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from the company s current expectations. For example, there can be no guarantee that IPI-549 will successfully complete necessary preclinical and clinical development phases or that any positive developments with IPI-549 will result in stock price appreciation. Management s expectations and, therefore, any forward-looking statements in this presentation could also be affected by risks and uncertainties relating to a number of other factors, including the following: Infinity s results of clinical trials and preclinical studies, including subsequent analysis of existing data and new data received from ongoing and future studies; Infinity s ability to obtain, maintain and enforce patent and other intellectual property protection for IPI-549; the content and timing of decisions made by the U.S. FDA and other regulatory authorities; Infinity s ability to obtain and maintain requisite regulatory approvals and to enroll patients in its clinical trials; unplanned cash requirements and expenditures; and development of agents by Infinity's competitors for diseases in which Infinity is currently developing or intends to develop IPI-549. These and other risks which may impact management s expectations are described in greater detail under the caption Risk Factors included in Infinity s quarterly report on Form 10-Q filed with the Securities and Exchange Commission (SEC) on November 7, 2017, and other filings filed by Infinity with the SEC. Any forwardlooking statements contained in this presentation speak only as of the date hereof, and Infinity expressly disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise. Infinity s website is Infinity regularly uses its website to post information regarding its business, product development programs and governance. Infinity encourages investors to use particularly the information in the section entitled Investors/Media, as a source of information about Infinity. References to in this presentation are not intended to, nor shall they be deemed to, incorporate information on into this presentation by reference. 2
3 IPI-549: Potential First-in-Class, Transformative Approach Within Immuno-Oncology Only potent, oral, selective PI3K-γ inhibitor in clinical development 1 Targeting macrophages with IPI-549 is a compelling approach to reducing pro-tumor immune suppression and increasing anti-tumor immune activation 2 Discovered and developed by Infinity Composition of matter patents into 2034 Encouraging clinical and translational data from monotherapy dose-escalation 3 Favorable tolerability profile alone and in combination with Opdivo Clinically active with objective response in monotherapy Initial translational data demonstrate on-mechanism reduction in immune suppression and increase in immune activation Robust Phase 1/1b study in advanced solid tumors 4 with new results anticipated starting in Q2 18 Evaluating as monotherapy and in combination with Opdivo Plan to evaluate ~ 200 patients Clinical and translational (including biopsy data) monotherapy and combination therapy data anticipated throughout January 8, Kaneda et al. Nature, 2016 Nov;539: De Henau et al. Nature, 2016 Nov;539: Hong et al., SITC NCT
4 Checkpoint Inhibitors Can Generate an Effective Anti-Tumor Immune Response in Patients With a Broad Range of Cancers Cancer Type NSCLC Gastric Liver Head and neck Bladder Kidney Breast (TN) Ovarian Melanoma CRC MSI hi Breast HR+ CRC non-msi hi Prostate NSCLC (EGFR Mu, ALK+) Patients Responsive to PD-1/PD-L1 Inhibitors 0 200, , , ,000 1,000,000 1,200,000 1,400,000 Patients Diagnosed Globally Per Year Source: GLOBOCAN Estimated cancer incidence in
5 But an Effective Immune Response is Not Generated in the Majority of Patients Cancer Type NSCLC Gastric Liver Head and neck Bladder Kidney Breast (TN) Ovarian Melanoma CRC MSI hi Breast HR+ CRC non-msi hi Prostate NSCLC (EGFR Mu, ALK+) Patients Responsive to PD-1/PD-L1 Inhibitors Patients Unresponsive to PD-1/PD-L1 Inhibitors 0 200, , , ,000 1,000,000 1,200,000 1,400,000 Patients Diagnosed Globally Per Year Source: GLOBOCAN Estimated cancer incidence in
6 And In Some Indications No Clinically Meaningful Immune Response Is Generated Cancer Type NSCLC Gastric Liver Head and neck Bladder Kidney Breast (TN) Ovarian Melanoma CRC MSI hi Breast HR+ CRC non-msi hi Prostate NSCLC (EGFR Mu, ALK+) Patients Responsive to PD-1/PD-L1 Inhibitors Patients Unresponsive to PD-1/PD-L1 Inhibitors 0 200, , , ,000 1,000,000 1,200,000 1,400,000 Patients Diagnosed Globally Per Year Source: GLOBOCAN Estimated cancer incidence in
7 Significant Patient Need Remains Given Limitations of Checkpoint Inhibitors NSCLC Gastric Liver Head and neck Bladder Opportunity to improve outcomes for: Kidney Breast (TN) ~1.2M Ovarian patients who respond to immune Patients Responsive checkpoint to PD-1/PD-L1 inhibitors Inhibitors Melanoma Patients Unresponsive to PD-1/PD-L1 Inhibitors CRC MSI hi ~8.0M patients unresponsive to immune checkpoint inhibitors Cancer Type Breast HR+ CRC non-msi hi Prostate NSCLC (EGFR Mu, ALK+) 0 200, , , ,000 1,000,000 1,200,000 1,400,000 Patients Diagnosed Globally Per Year Source: GLOBOCAN Estimated cancer incidence in
8 Targeting the Myeloid/Macrophage Compartment Is Emerging As a Compelling Approach to Overcoming Limitations of Checkpoint Inhibitors Tumors evade immune attack through multiple mechanisms, with a key role played by the myeloid/macrophage compartment Pro-tumor macrophages dominate in the tumor microenvironment and prevent anti-tumor attack Targeting macrophages to enhance anti-tumor immune attack can be achieved in two ways Reduce pro-tumor macrophage function Increase anti-tumor macrophage function 8
9 There Are a Growing Number of Macrophage Targeted Approaches in Development to Address the Limitations of Checkpoint Inhibitors Immuno-Oncology Therapies in Development or Launched 200 ~180 Number of Molecules T cell Targeted IPI-549 ~30 Myeloid / Macrophage Targeted IPI-549 is only selective PI3Kgamma inhibitor in development 9
10 IPI-549 Is Differentiated Within Macrophage Targeted Approaches Immuno-Oncology Therapies in Development or Launched 200 ~180 Number of Molecules T cell Targeted IPI-549 ~30 Myeloid / Macrophage Targeted IPI-549 is only selective PI3Kgamma inhibitor in development 10
11 IPI-549 Is Differentiated Within Macrophage Targeted Approaches Distinct role in reducing pro-tumor macrophage function and increasing anti-tumor macrophage function Immuno-Oncology Therapies in Development or Launched 200 ~180 Targeting macrophages to enhance anti-tumor immune attack can be achieved in two ways Number of Molecules T cell Targeted IPI-549 ~30 Myeloid / Macrophage Targeted IPI-549 is only selective PI3Kgamma inhibitor in development Reduce pro-tumor macrophage function e.g. CSF1r + Increase anti-tumor macrophage function e.g. CD40 + IPI
12 IPI-549 Is Differentiated Within Macrophage Targeted Approaches Distinct role in reducing pro-tumor macrophage function and increasing anti-tumor macrophage function Immuno-Oncology Therapies in Development or Launched 200 ~180 Targeting macrophages to enhance anti-tumor immune attack can be achieved in two ways Number of Molecules T cell Targeted IPI-549 ~30 Myeloid / Macrophage Targeted IPI-549 is only selective PI3Kgamma inhibitor in development Reduce pro-tumor macrophage function e.g. CSF1r + Increase anti-tumor macrophage function e.g. CD40 + IPI
13 IPI-549 Is Differentiated Within Macrophage Targeted Approaches Distinct role in reducing pro-tumor macrophage function and increasing anti-tumor macrophage function Immuno-Oncology Therapies in Development or Launched 200 ~180 Targeting macrophages to enhance anti-tumor immune attack can be achieved in two ways Number of Molecules T cell Targeted IPI-549 ~30 Myeloid / Macrophage Targeted IPI-549 is only selective PI3Kgamma inhibitor in development Reduce pro-tumor macrophage function e.g. CSF1r + Increase anti-tumor macrophage function e.g. CD40 + IPI Enhanced anti-tumor attack with IPI
14 Reprogramming Tumor-Associated Macrophages by Targeting PI3K-γ with IPI
15 IPI-549: First in Class, Oral Selective Inhibitor of PI3K-γ Assay PI3K-γ PI3K-α PI3K-β PI3K-δ Binding Affinity Kd (nm) Biochemical IC 50 (nm) >8421 Cellular IC 50 (nm) DeHenau et al. AACR 2016 # X selectivity in cellular assay Chemical Structure of IPI-549 Composition of matter patents into 2034 Evans et al. ACS Med. Chem. Lett. (2016). 15
16 IPI-549 Reprograms Macrophages Resulting in Reduced Pro-Tumor Immune Suppression and Increased Anti-Tumor Immune Activation Pro-tumor (M2) macrophages Suppressed T cells Tumor cells Kaneda et al. Nature, 2016 Nov;539:
17 IPI-549 Reprograms Macrophages Resulting in Reduced Pro-Tumor Immune Suppression and Increased Anti-Tumor Immune Activation Anti-tumor (M1) macrophages Activated T cells Tumor cells IPI-549 Kaneda et al. Nature, 2016 Nov;539:
18 IPI-549 Reprograms Macrophages Resulting in Reduced Pro-Tumor Immune Suppression and Increased Anti-Tumor Immune Activation Kaneda et al. Nature, 2016 Nov;539:
19 IPI-549 Monotherapy Demonstrates Tumor Growth Delay in the Lewis Lung Carcinoma Model 2,500 Tumor volume (mm 3 ) 2,000 1,500 1, * Vehicle n=13 15 mg/kg QD n=15 p < Treatment start Day post-implant IPI-549 effects are both macrophage-dependent and T cell-dependent Kutok et al., Immune Microenvironment: Transforming the Future of Cancer Therapies Meeting,
20 IPI-549 Monotherapy Demonstrates Tumor Growth Delay in Multiple Syngeneic Solid Tumor Models Cancer Type Cell Line % Tumor Growth Inhibition Range [n experiments] Lung LLC-luc brei 28-52% [10] Colon MC % [3] Colon CT % [12] Breast 4T1-luc 19-38% [6] Melanoma B16-GMCSF 24-56% [6] De Henau et al. Nature, 2016 Nov;539:
21 Preclinical Data Demonstrate Targeting PI3K-γ in Macrophages Overcomes Resistance to Checkpoint Blockade De Henau et al. Nature, 2016 Nov;539:
22 Pro-Tumor Macrophages Drive Checkpoint Inhibitor Resistance and Can Be Overcome by IPI-549 Treatment, Providing Survival Benefit 2000 Macrophage-Rich Breast Cancer (4T1) Model Reduced Tumor Growth Enhanced Survival Tumor Size (mm 3 ) PD-1 Vehicle IPI-549 (15 mg/kg) PD-1 + IPI-549 * * ** Percent Survival IPI anti-ctla4 + anti-pd-1 Anti-CTLA4 + anti PD-1 Vehicle **** * **** **** Days post-implant Days post-implant IPI-549 in combination with anti-pd-1 and anti-ctla4 therapies significantly extends survival with 30% complete regression * P <0.05, ** P <0.01, ****P < De Henau et al. Nature, 2016 Nov;539:
23 Key Preclinical Takeaways Reprograms macrophages from pro-tumor (M2) function to the anti-tumor (M1) function Demonstrated monotherapy activity Greater tumor growth inhibition and survival in combination with checkpoint inhibitors Reverses resistance to checkpoint inhibitors 23
24 Initial Clinical and Translational Data 24
25 IPI Sites/Investigators Investigator(s) Jedd Wolchok, MD PhD (PI) Michael Postow, MD David Hong, MD Anthony W. Tolcher MD FRCP FACP Amita Patnaik, MD Geoff Shapiro, MD PhD Steve Hodi, MD PhD Keith Flaherty MD Ryan Sullivan, MD James Miers, MD Toni Ribas, MD PhD Bartosz Chmielowski, MD Ezra Cohen, MD Institution MSKCC MDACC South Texas Accelerated Research Therapeutics (START) DFCI MGH BIDMC UCLA UCSD 25
26 IPI-549 Phase 1/1b Study Monotherapy Dose Escalation in Solid Tumors 40 mg QD 60 mg QD Completed No DLTs - MTD was not identified Expansion initiated based on PK/PD 30 mg QD 10 mg QD 15 mg QD 20 mg QD Endpoints PK/PD Safety Activity Peripheral blood samples for translational analysis 3+3 design N=19 total, 18 evaluable Hong et al., SITC
27 Safety Summary (N=19) Data as of October 18, 2017 IPI-549 monotherapy has been well tolerated (doses up to 60 mg QD) No DLTs - MTD was not identified Majority of reported AEs have been Grade 1-2 No treatment-related SAEs or treatment-related deaths 2 patients discontinued study drug due to treatment-related AEs Grade 2 rash and Grade 2 ALT/AST increase Grade 3 ALT/AST increase Hong et al., SITC
28 IPI-549 Phase 1/1b Trial in ~200 Patients in Advanced Solid Tumors Dose Escalation Peripheral Blood Samples Monotherapy* 10 mg to 60 mg QD 3+3 design RP2D: 60 mg QD Expansion Peripheral Blood Samples and Mandatory Pre-Treatment and On-Treatment Biopsies All Solid Tumors NSCLC Melanoma Checkpoint inhibitor-resistant**** Combination IPI-549* + Nivolumab** 6+6 design Completed Enrolled Enrolling RP2D: 40 mg QD + Nivolumab** SCCHN TNBC Mesothelioma Adrenocortical Carcinoma Checkpoint inhibitor-naïve Checkpoint inhibitor-independent * 28 day cycles, continuous QD dosing ** Flat-dose 240 mg Q2W *** Enrollment expected to initiate in Q **** Must have de novo or acquired resistance to immediately prior anti-pd-1/anti-pd-l1 therapy MDSC High*** Prospectively identified 28
29 New Cohort of Patients Selected Based on High Myeloid Derived Suppressor Cell (MDSC) Baseline Status Is Being Initiated MDSCs limit the response to immune therapies and IPI-549 can overcome their suppressive effect 1 Poor response to checkpoint inhibitor therapy is correlated with the presence of high pre-treatment levels of MDSCs 2 Responses to IPI-549 were seen in patients with high basal levels of MDSCs, alone and in combination with nivolumab New cohort of MDSC high patients to be treated with IPI-549 in combination with nivolumab 1. De Henau et al. Nature, 2016 Nov;539:443. Talmadge and Gabrilovich Nat Rev Canc 2013, 13: Kitano et al ASCO annual meeting #2518, 2013; Postow et al NEJM 2012, 366;10; Kitano et al. Cancer Immunol Res. 2014, 2(8):
30 IPI-549 Monotherapy Dose Escalation Time on Study (N=19) Dose (mg) Tumor Type 15 Adenoid 20 Mesothelioma MSS 20 Colorectal 15 Ovarian 10 Endometrial 20 Endometrial 40 Head & Neck 60 Breast 30 Neuroendocrine MSS 30 Colorectal 30 Adenoid 10 Ovarian 60 Endometrial 60 Esophageal 40 Merkel Cell 10 Pancreatic 15 Pancreatic 40 Ovarian 40 Head & Neck Weeks On Study Partial Response Disease Progression Discontinued Drug Related Discontinued Week Partial Response Occurred Data as of October 18, 2017 Hong et al., SITC
31 IPI-549 Monotherapy Dose Escalation Time on Study (N=19) Dose (mg) Tumor Type 15 Adenoid 20 Mesothelioma MSS 20 Colorectal 15 Ovarian 10 Endometrial 20 Endometrial 40 Head & Neck 60 Breast 30 Neuroendocrine MSS 30 Colorectal 30 Adenoid 10 Ovarian 60 Endometrial 60 Esophageal 40 Merkel Cell 10 Pancreatic 15 Pancreatic 40 Ovarian 40 Head & Neck Weeks Partial Response Disease Progression Discontinued Drug Related Discontinued Week Partial Response Occurred Weeks Clinical benefit defined as patients who have not progressed at 16 weeks (8/18 evaluable patients) On Study Data as of October 18, 2017 Hong et al., SITC
32 Partial Response in a Patient with Advanced Peritoneal Mesothelioma 50 yo Male with Peritoneal Mesothelioma (epithelioid type) Original Dx October prior regimens, last regimen pemetrexed/carboplatin (duration of last prior therapy 2.5 months) Started on 20 mg IPI-549 August 2016 % Change 10% 0% -10% -20% -30% 0% % Change in Lesion Size (RECIST) 3% -6% -12% -23% -25% -36% PR Patient remains on study as of January 8, % -50% -42% BL C3 C5 C7 C9 C11 C13 C15 Hong et al., SITC Cycle Number (1 Cycle = 4 Weeks) 32
33 Partial Response in a Patient with Advanced Peritoneal Mesothelioma Radiologic Evidence of Tumor Reduction in Abdominal Cavity Baseline End of Cycle 15 Hong et al., SITC
34 Improvement of Malignant Pleural Effusions and Ascites in Heavily Pre-Treated Patient with KRAS+ MSS Colorectal Cancer Stage IV diagnosed July 2012 with 8 prior regimens (duration of last prior therapy~2 months) Extensive peritoneal carcinoma with ascites; bilateral pleural effusion, as well as liver and lung lesions Remained on monotherapy for 36 weeks Baseline End of Cycle 2 Hong et al., SITC
35 Partial Response in Patient With Adrenocortical Carcinoma Treated With IPI mg QD and Nivolumab 57 year old male diagnosed with adrenocortical carcinoma July 2013 underwent surgery 10% 0% % Change in Lesion Size (RECIST) 0% April 2014, six cycles chemotherapy (Adriamycin, Platinum, Etoposide and Mitotane) with maintenance Mitotane until February 2017 % Change -10% -20% -30% -40% -37% PR No prior anti-pd1/pd-l1 therapy Patient remains on study as of January 8, 2018 Hong, Infinity Investor Presentation SITC % -60% -70% -55% -60% BL C3 C5 C7 Cycle Number (1 Cycle = 4 Weeks) 35
36 Partial Response in Patient With Adrenocortical Carcinoma Treated With IPI mg QD and Nivolumab Radiologic Evidence of Tumor Reduction in Liver Metastases Extensive metastatic disease including liver (typically poor prognosis), lung, retroperitoneum, spleen, lymph nodes Baseline Cycle 3 Day 1 Courtesy of Dr. Ryan Sullivan/Dr. Dejan Juric Hong, Infinity Investor Presentation SITC
37 Initial Translational Data in Peripheral Blood Following Monotherapy Treatment with IPI-549 Support the Dual Mechanism of Action of IPI-549 Targeting macrophages to enhance anti-tumor immune attack can be achieved in two ways Reduce pro-tumor macrophage function IPI IPI-549 reduces immune suppression Reinvigoration (proliferation) of exhausted CD8+ T-cells Increase anti-tumor macrophage function + IPI-549 increases immune activation Up-regulation of interferon-gamma responsive factors Increased myeloid cell activation markers, which are associated with clinical benefit (>16 weeks on study) Hong et al., SITC
38 Encouraging Early Phase 1/1b Data for IPI-549 from Dose Escalations Monotherapy* Combination Therapy PK/PD Maximal and sustained inhibition of PI3K-γ signaling IPI-549 PK/PD unaffected in the presence of nivolumab Safety Favorable safety profile in patients treated up to 60 mg QD Combination well tolerated 40 mg selected as recommended Phase 2 dose Activity Objective partial response in patient with mesothelioma, with 44% of patients on IPI-549 for over four months Objective partial response in patient with adrenocortical cancer Expansion cohorts initiated based on signals of clinical activity Hong et al., SITC New Results Anticipated Starting in Q
39 2018 Milestones and Financial Guidance 39
40 2018: Multiple Clinical Data Readouts Anticipated Starting in 2Q 2Q2018 Report data from the monotherapy expansion cohort, including clinical and translational data from paired tumor biopsies Report data from the combination dose-escalation Report initial data from combination expansion cohorts 2H2018 Report additional combination expansion data with more mature clinical and translational data including insights from paired tumor biopsies 40
41 2018 Financial Guidance Cash and investments at 12/31/17 (unaudited): $57.6 million Net loss: $40 million to $50 million Year-end cash: $10 million and $20 million Cash runway: Into Q The company s 2018 financial guidance is provided as of January 8, 2018, excludes additional funding or business development activities and does not include the potential $22 million milestone from Verastem upon the first regulatory approval of duvelisib. Verastem has provided its expectation that it plans to submit a New Drug Application to the U.S. Food and Drug Administration for duvelisib in the first quarter of
42 IPI-549: Potential First-in-Class, Transformative Approach Within Immuno-Oncology Only potent, oral, selective PI3K-γ inhibitor in clinical development 1 Encouraging clinical and translational data from monotherapy dose-escalation 2 Robust Phase 1/1b study in advanced solid tumors 3 with new results anticipated starting in Q January 8, Hong et al., SITC NCT
43 Pioneering a first-in-class, oral immuno-oncology therapy JPMorgan Healthcare Conference January 2018
Society for Immunotherapy of Cancer (SITC) Annual Meeting November 10, 2017
Society for Immunotherapy of Cancer (SITC) Annual Meeting November 10, 2017 Forward-Looking Statements This presentation contains forward-looking statements within the meaning of The Private Securities
More informationBuilding a Fully Integrated Biopharmaceutical Company. June 2014
Building a Fully Integrated Biopharmaceutical Company June 2014 Forward-Looking Statements This presentation contains forward-looking statements within the meaning of The Private Securities Litigation
More informationPresenter Disclosure Information
Monotherapy Dose Escalation Clinical and Translational Data from the First-in-Human Study in Advanced Solid Tumors of IPI-549, an Oral, Selective PI3K-γ Inhibitor Targeting Tumor Macrophages David S. Hong,
More informationLeerink Immuno-Oncology Roundtable Conference
Leerink Immuno-Oncology Roundtable Conference September 28, 2017 NASDAQ:FPRX Forward-Looking Statements Disclaimer This presentation contains forward-looking statements within the meaning of the Private
More informationWells Fargo Healthcare Conference September 6, 2018
Wells Fargo Healthcare Conference September 6, 2018 Safe Harbor Statement To the extent that statements contained in this presentation are not descriptions of historical facts regarding TESARO, they are
More informationInvestor Webcast: Initial Data from Phase 1a/1b Trial of Cabiralizumab/OPDIVO and Early Efficacy Signal in Pancreatic Cancer.
Investor Webcast: Initial Data from Phase 1a/1b Trial of Cabiralizumab/OPDIVO and Early Efficacy Signal in Pancreatic Cancer November 8, 2017 NASDAQ:FPRX Forward-Looking Statements Disclaimer This presentation
More informationInfinity Highlights Promising Preclinical Hedgehog Data and Announces First Quarter Financial Results
Infinity Highlights Promising Preclinical Hedgehog Data and Announces First Quarter Financial Results Heat Shock Protein 90 Program Continues to Advance Toward Potential Registration Trial CAMBRIDGE, Mass.,
More informationMore cancer patients are being treated with immunotherapy, but
Bristol-Myers Squibb and Five Prime Present Phase 1a/1b Data Evaluating Cabiralizumab (anti-csf-1 receptor antibody) with Opdivo (nivolumab) in Patients with Advanced Solid Tumors PRINCETON, N.J. & SOUTH
More informationThe Galectin-3 Inhibitor GR-MD-02 for Combination Cancer Immunotherapy
The Galectin-3 Inhibitor GR-MD-02 for Combination Cancer Immunotherapy Supplemental Information to Corporate Presentation February 6, 2018 NASDAQ: GALT www.galectintherapeutics.com 2018 2017 Galectin Therapeutics
More informationMerck ASCO 2015 Investor Briefing
Merck ASCO 2015 Investor Briefing Forward-Looking Statement This presentation includes forward-looking statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation
More informationFive Prime Therapeutics, Inc. Corporate Overview
Five Prime Therapeutics, Inc. Corporate Overview June 2015 NASDAQ:FPRX Forward-Looking Statements Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities
More informationADAPTIMMUNE INVESTOR PRESENTATION. August 2016
ADAPTIMMUNE INVESTOR PRESENTATION August 2016 DISCLAIMER This presentation contains forward-looking statements, as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA),
More informationCiti s 13 th Annual Biotech Conference September 5, 2018
Citi s 13 th Annual Biotech Conference September 5, 2018 Safe Harbor Statement To the extent that statements contained in this presentation are not descriptions of historical facts regarding TESARO, they
More informationNewLink Genetics Corporation
Cantor Fitzgerald 2018 Global Healthcare Conference NewLink Genetics Corporation NASDAQ: NLNK October 3, 2018 Cautionary Note Regarding Forward-Looking Statements This presentation contains forward-looking
More informationFull Year 2017 Financial Results. February 14, 2018
Full Year 2017 Financial Results February 14, 2018 Agios Conference Call Participants Prepared Remarks Introduction KENDRA ADAMS, Sr. Director, Investor Relations 2018 Vision & Key Milestones DAVID SCHENKEIN,
More informationNewLink Genetics Corporation
Cantor Fitzgerald Global Healthcare Conference NewLink Genetics Corporation NASDAQ: NLNK September 25, 2017 Forward-Looking Disclaimer This presentation contains forward-looking statements of NewLink that
More informationImmunologic Effects of Clinical Stage FAK & PI3K-Delta/Gamma Inhibitors
1 Immunologic Effects of Clinical Stage FAK & PI3K-Delta/Gamma Inhibitors Jonathan Pachter, Ph.D - Chief Scientific Officer 3rd Annual Immuno-Oncology Congress, May 24, 2018 Disclosures 2 I am an employee
More informationDetermined to realize a future in which people with cancer live longer and better than ever before CORPORATE PRESENTATION SEPTEMBER 2017
Determined to realize a future in which people with cancer live longer and better than ever before CORPORATE PRESENTATION SEPTEMBER 2017 1 Forward-looking statements disclosure This presentation contains
More informationLeading the Next Wave of Biotech Breakthroughs
Leading the Next Wave of Biotech Breakthroughs Corporate Extensive corporate assets Platforms Pipeline Partnerships Building a sustainable global business Platform licenses represent a source of non-dilutive
More informationCorporate Presentation October 2018 Nasdaq: ADXS
Innovations in Immuno-Oncology Corporate Presentation October 2018 Nasdaq: ADXS Forward-Looking Statements This presentation contains forward-looking statements, including, but not limited to, statements
More informationDetermined to realize a future in which people with cancer live longer and better than ever before CORPORATE PRESENTATION JUNE 2017
Determined to realize a future in which people with cancer live longer and better than ever before CORPORATE PRESENTATION JUNE 2017 1 Forward-looking statements disclosure This presentation contains forward-looking
More informationCorporate Overview. June 2017 NASDAQ:FPRX
Corporate Overview June 2017 NASDAQ:FPRX Forward-Looking Statements Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of
More informationThird Quarter 2018 Financial Results. November 1, 2018
Third Quarter 2018 Financial Results November 1, 2018 Agios Conference Call Participants Prepared Remarks Introduction RENEE LECK, Associate Director, Investor Relations Business Highlights & 2018 Key
More informationDawson James Conference
Dawson James Conference October 2018 Forward-looking Statements Except for historical information, this presentation contains forward-looking statements, which reflect IMV s current expectations regarding
More informationREWRITING CANCER TREATMENT THROUGH EPIGENETIC MEDICINES
REWRITING CANCER TREATMENT THROUGH EPIGENETIC MEDICINES May 18, 2017 Molecularly Defined Solid Tumor Program Update FORWARD-LOOKING STATEMENTS Any statements in this press release about future expectations,
More informationAVEO Oncology Announces Strategic Restructuring. AVEO to Host Conference Call Wednesday, June 5 at 8:30 a.m. ET
NEWS RELEASE FOR IMMEDIATE RELEASE AVEO Oncology Announces Strategic Restructuring AVEO to Host Conference Call Wednesday, June 5 at 8:30 a.m. ET CAMBRIDGE, Mass., June 4, 2013 AVEO Oncology (NASDAQ: AVEO)
More informationCORPORATE PRESENTATION
CORPORATE PRESENTATION June 2017 FORWARD LOOKING SAFE HARBOR STATEMENT This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.
More information2016 Year-End Results and Conference Call. March 14, 2017
2016 Year-End Results and Conference Call March 14, 2017 Forward Looking Statement This communication contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform
More informationDetermined to realize a future in which people with cancer live longer and better than ever before
Determined to realize a future in which people with cancer live longer and better than ever before 3Q 2018 EARNINGS PRESENTATION NOVEMBER 2018 1 Forward-looking statements disclosure This presentation
More informationCorporate Presentation September Nasdaq: ADXS
Corporate Presentation September 2018 Nasdaq: ADXS Forward-Looking Statements This presentation contains forward-looking statements, including, but not limited to, statements regarding the ability and
More informationFirst Phase 3 Results Presented for a PD-1 Immune Checkpoint Inhibitor
September 30, 2014 Positive Phase 3 Data for Opdivo (nivolumab) in Advanced Melanoma Patients Previously Treated with Yervoy @ (ipilimumab) Presented at the ESMO 2014 Congress First Phase 3 Results Presented
More informationImmune Checkpoint Inhibitors: The New Breakout Stars in Cancer Treatment
Immune Checkpoint Inhibitors: The New Breakout Stars in Cancer Treatment 1 Introductions Peter Langecker, MD, PhD Executive Medical Director, Global Oncology Clinipace Worldwide Mark Shapiro Vice President
More informationCorporate Presentation: Jefferies Global Healthcare Conference June 7, 2018
Corporate Presentation: Jefferies Global Healthcare Conference June 7, 2018 2018 CytomX Therapeutics, Inc. 1 Forward Looking Statements Special Note Regarding Forward-Looking Statements This presentation
More informationDetermined to realize a future in which people with cancer live longer and better than ever before
Determined to realize a future in which people with cancer live longer and better than ever before 4Q 2016 EARNINGS PRESENTATION MARCH 2017 1 Forward-looking statements disclosure This presentation contains
More informationICONIC: Biologic and clinical activity of first in class ICOS agonist antibody JTX /- nivolumab (nivo) in patients with advanced cancers
ICONIC: Biologic and clinical activity of first in class ICOS agonist antibody JTX-211 +/- nivolumab (nivo) in patients with advanced cancers Timothy A. Yap 1, Howard A. Burris 2, Shivaani Kummar 3, Gerald
More informationLION. Corporate Presentation June 2016 BIOTECHNOLOGIES. Leadership & Innovation in Oncology
LION BIOTECHNOLOGIES Leadership & Innovation in Oncology Corporate Presentation June 2016 Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private
More informationCorporate Overview May 8, 2014
0 Corporate Overview May 8, 2014 NASDAQ: CRIS Forward Looking Statements This presentation contains statements about Curis future expectations, plans and prospects that constitute forward-looking statements
More informationDetermined to realize a future in which people with cancer live longer and better than ever before Q Conference Call
Reimagining Cancer Treatment Determined to realize a future in which people with cancer live longer and better than ever before Q1 2016 Conference Call 1 Forward-Looking Statements Disclosure This presentation
More informationCorporate Overview. June 2018 NASDAQ:FPRX
Corporate Overview June 2018 NASDAQ:FPRX Forward-Looking Statements Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of
More informationJefferies 2018 Healthcare Conference. June 6, 2018
Jefferies 2018 Healthcare Conference z June 6, 2018 This presentation includes forward-looking statements regarding Nektar s proprietary drug candidates, the timing of the start and conclusion of ongoing
More information2019 ASCO-SITC. Nektar Therapeutics Investor & Analyst Call. March 1, 2019
Nektar Therapeutics Investor & Analyst Call March 1, 2019 This presentation includes forward-looking statements regarding Nektar s proprietary drug candidates, the timing of the start and conclusion of
More informationKaryopharm Reports Second Quarter 2015 Financial Results and Highlights Recent Progress
August 10, 2015 Karyopharm Reports Second Quarter 2015 Financial Results and Highlights Recent Progress - Positive Selinexor Clinical Data Presented across Several Difficult to Treat Cancers - - Provides
More informationMERCK ONCOLOGY OVERVIEW ASCO 2018 JUNE 4, 2018
MERCK ONCOLOGY OVERVIEW ASCO 218 JUNE 4, 218 Forward-Looking Statement of Merck & Co., Inc., Kenilworth, NJ, USA This presentation of Merck & Co., Inc., Kenilworth, N.J., USA (the company ) includes forward
More informationCombining HS-110 and anti-pd-1 in NSCLC. September 1, 2015
Combining HS-110 and anti-pd-1 in NSCLC September 1, 2015 Forward Looking Statements This presentation includes statements that are, or may be deemed, forward-looking statements. In some cases, these forward-looking
More informationVeriStrat Poor Patients Show Encouraging Overall Survival and Progression Free Survival Signal; Confirmatory Phase 2 Study Planned by Year-End
AVEO and Biodesix Announce Exploratory Analysis of VeriStrat-Selected Patients with Non-Small Cell Lung Cancer in Phase 2 Study of Ficlatuzumab Presented at ESMO 2014 Congress VeriStrat Poor Patients Show
More informationASCO 2018 Investor Meeting
ASCO 2018 Investor Meeting June 4, 2018 1 Forward-Looking Information This presentation contains statements about the Company s future plans and prospects that constitute forward-looking statements for
More informationInducing Tumor-Specific Ischemic Necrosis to Enhance the Efficacy of Checkpoint Inhibitors and Chemotherapy
Inducing Tumor-Specific Ischemic Necrosis to Enhance the Efficacy of Checkpoint Inhibitors and Chemotherapy Company Overview, September 2018 Safe Harbor Statement This presentation contains forward-looking
More informationTargeting the genetic and immunological drivers of cancer
NASDAQ: MRTX Targeting the genetic and immunological drivers of cancer Corporate Presentation April 2019 1 Safe Harbor Statement Certain statements contained in this presentation, other than statements
More informationNovel RCC Targets from Immuno-Oncology and Antibody-Drug Conjugates
Novel RCC Targets from Immuno-Oncology and Antibody-Drug Conjugates Christopher Turner, MD Vice President, Clinical Science 04 November 2016 Uveal Melanoma Celldex Pipeline CANDIDATE INDICATION Preclinical
More informationGenomic Health. Kim Popovits, Chairman, CEO and President
Genomic Health Kim Popovits, Chairman, CEO and President Safe Harbor Statement Various remarks that we make in this presentation that are not historical, including those about our future financial and
More informationThird Quarter 2015 Earnings Call. November 9, 2015
Third Quarter 2015 Earnings Call November 9, 2015 Forward-Looking Statements All of the statements in this presentation that are not statements of historical facts constitute forward-looking statements
More informationArQule CorporateUpdate
ArQule April 2015 1 ArQule CorporateUpdate Safe Harbor This presentation and other statements by ArQule may contain forwardlooking statements within the meaning of the Private Securities Litigation Reform
More informationCorporate Presentation: 2018 Wedbush PacGrow Healthcare Conference August 14, 2018
Corporate Presentation: 2018 Wedbush PacGrow Healthcare Conference August 14, 2018 2018 CytomX Therapeutics, Inc. 1 Forward Looking Statements Special Note Regarding Forward-Looking Statements This presentation
More informationArQule Jefferies Global Healthcare Conference June 2015
ArQule Jefferies Global Healthcare Conference June 2015 1 ArQule Corporate Update Safe Harbor This presentation and other statements by ArQule may contain forward-looking statements within the meaning
More informationCalithera Biosciences. January 2019
Calithera Biosciences January 2019 Forward-Looking Statements This presentation and the accompanying oral commentary contain forward looking statements for purposes of the safe harbor provisions of the
More informationReimagining Cancer Treatment. Determined to realize a future in which people with cancer live longer and better than ever before
Reimagining Cancer Treatment Determined to realize a future in which people with cancer live longer and better than ever before Cantor Fitzgerald 2nd Annual Healthcare Conference July 13, 2016 Forward-Looking
More informationSyndax Announces Updated Results from Phase 2 ENCORE 601 Trial of Entinostat in Combination with KEYTRUDA (pembrolizumab)
Syndax Announces Updated Results from Phase 2 ENCORE 601 Trial of Entinostat in Combination with KEYTRUDA (pembrolizumab) Ongoing ENCORE 601 biomarker analyses suggest enhanced clinical benefit in subpopulation
More informationInvestor Meetings October 2018
Investor Meetings October 2018 Safe Harbor Statement To the extent that statements contained in this presentation are not descriptions of historical facts regarding TESARO, they are forward-looking statements
More informationIdera Pharmaceuticals
Idera Pharmaceuticals ILLUMINATE-204 Clinical Data Update December 2018 Forward Looking Statements and Other Important Cautions This presentation contains forward-looking statements within the meaning
More informationNewLink Genetics Corporation
Stifel Healthcare Conference Presentation NewLink Genetics Corporation NASDAQ: NLNK November 13, 2018 Cautionary Note Regarding Forward-Looking Statements This presentation contains forward-looking statements
More informationBank of America Merrill Lynch 2018 Health Care Conference. Reinventing Therapeutic Antibodies for the Treatment of Cancer
Bank of America Merrill Lynch 2018 Health Care Conference Reinventing Therapeutic Antibodies for the Treatment of Cancer May 17, 2018 1 Forward Looking Statements Special Note Regarding Forward-Looking
More informationNOVEL CHECKPOINTS IN IMMUNO-ONCOLOGY KIR NKG2A. C5aR. NKp46 HALF-YEAR RESULTS. Tumor antigen KIR3DL2 CD39 MICA/B CD73 SEPTEMBER 18, 2017
NOVEL CHECKPOINTS IN IMMUNO-ONCOLOGY KIR NKG2A NKp46 C5aR Tumor antigen HALF-YEAR RESULTS KIR3DL2 MICA/B CD73 CD39 SEPTEMBER 18, 2017 Page 2 FORWARD LOOKING STATEMENT This document has been prepared by
More informationASCO 2014 Highlights*
ASCO 214 Highlights* Investor Meeting June 2, 214 *American Society of Clinical Oncology, May 3 June 3, 214 Forward-Looking Information During this meeting, we will make statements about the Company s
More informationMarch Corporate Presentation
March 2017 Corporate Presentation Disclaimer This presentation contains forward-looking statements, as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements
More informationCheckpoint Regulators Cancer Immunotherapy takes centre stage. Dr Oliver Klein Department of Medical Oncology 02 May 2015
Checkpoint Regulators Cancer Immunotherapy takes centre stage Dr Oliver Klein Department of Medical Oncology 02 May 2015 Adjuvant chemotherapy improves outcome in early breast cancer FDA approval of Imatinib
More informationJuly, ArQule, Inc.
July, 2012 Safe Harbor This presentation and other statements by ArQule may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to clinical
More informationMyeloid Differentiation Observed, Including Induction of CD38 in 85% of Evaluable Patients
December 10, 2017 Syros Announces Initial Clinical Data from Ongoing Phase 2 Trial of SY-1425 Showing Biological and Clinical Activity as Single Agent in Genomically Defined AML and MDS Patients Clinical
More informationCalithera Biosciences
Calithera Biosciences March 2019 Forward-Looking Statements This presentation and the accompanying oral commentary contain forward looking statements for purposes of the safe harbor provisions of the Private
More informationAACR 2018 Investor Meeting
AACR 218 Investor Meeting April 16, 218 1 Forward-Looking Information This presentation contains statements about the Company s future plans and prospects that constitute forward-looking statements for
More informationInvestor Call. May 19, Nasdaq: IMGN
Investor Call May 19, 2017 Nasdaq: IMGN Forward-Looking Statements This presentation includes forward-looking statements based on management's current expectations. These statements include, but are not
More informationAttached from the following page is the press release made by BMS for your information.
June 2, 2015 Opdivo (nivolumab) Demonstrates Superior Survival Compared to Standard of Care (docetaxel) for Previously-Treated Squamous Non-Small Cell Lung Cancer in Phase III Trial (PRINCETON, NJ, May
More informationInarigivir ACHIEVE Trial Results and HBV Clinical Program Update. August 2, 2018
Inarigivir ACHIEVE Trial Results and HBV Clinical Program Update August 2, 2018 FORWARD LOOKING STATEMENT This presentation includes forward-looking statements within the meaning of the Private Securities
More informationNewLink Genetics Corporation Provides Operational Update and Reports Second Quarter 2015 Financial Results
July 31, 2015 NewLink Genetics Corporation Provides Operational Update and Reports Second Quarter 2015 Financial Results -Management to Host Conference Call Today at 8:30 a.m. ET- AMES, Iowa, July 31,
More informationONO PHARMACEUTICAL CO., LTD. and Bristol-Myers Squibb Announce Strategic Immuno-Oncology Collaboration in Japan, South Korea and Taiwan
ONO PHARMACEUTICAL CO., LTD. and Bristol-Myers Squibb Announce Strategic Immuno-Oncology Collaboration in Japan, South Korea and Taiwan Companies to develop and commercialize Opdivo (nivolumab), ipilimumab,
More informationCorporate Presentation March 2016
Corporate Presentation March 2016 Forward Looking Safe Harbor Statement This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.
More informationDisclosures. Speakers Bureau. Clinical Trial Research Funding
Interim Results of an Ongoing Phase 1, Dose Escalation Study of MGA271 (Enoblituzumab), an Fc optimized Humanized Anti B7 H3 Monoclonal Antibody, in Patients with Advanced Solid Cancer Powderly J a, Cote
More informationGSK Oncology. Axel Hoos, MD, PhD Senior Vice President, Oncology R&D. March 8, 2017
GSK Oncology Axel Hoos, MD, PhD Senior Vice President, Oncology R&D March 8, 217 GSK pipeline Oncology R&D Strategy Maximizing survival through transformational medicines and combinations Cancer Epigenetics
More information33 rd Annual J.P. Morgan Healthcare Conference. January 2015
33 rd Annual J.P. Morgan Healthcare Conference January 2015 Forward-looking Statements This presentation contains forward-looking statements, which express the current beliefs and expectations of management.
More informationOncology Therapeutics without Compromise APRIL 2011
Oncology Therapeutics without Compromise APRIL 2011 Forward Looking Statements This presentation contains forward-looking statements that involve substantial risks and uncertainties, including among other
More informationU.S. Food and Drug Administration Accepts Supplemental Biologics License Application for Opdivo
U.S. Food and Drug Administration Accepts Supplemental Biologics License Application for Opdivo (nivolumab) in Patients with Previously Untreated Advanced Melanoma Application includes CheckMate -066,
More informationCelldex Provides Corporate Update and Reports First Quarter 2018 Results
May 10, 2018 Celldex Provides Corporate Update and Reports First Quarter 2018 Results HAMPTON, N.J., May 10, 2018 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported business and
More informationHighlights from AACR 2015: The Emerging Potential of Immunotherapeutic Approaches in Non-Small Cell Lung Cancer
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
More informationU.S. Food and Drug Administration Accepts Supplemental Biologics License Application. for Opdivo (nivolumab)
September 3, 2015 U.S. Food and Drug Administration Accepts Supplemental Biologics License Application for Opdivo (nivolumab) in Previously Treated Non-Squamous Non-Small Cell Lung Cancer Patients (PRINCETON,
More informationTargeting and Treating Cancer
Targeting and Treating Cancer Mark R. Baker, Chief Executive Officer Jefferies Healthcare Conference June 2015 Disclosure Notice This presentation may contain projections and other forward-looking statements
More informationRexahn Pharmaceuticals Overview
Rexahn Pharmaceuticals Overview May 2018 Safe Harbor Statement The statements that follow (including projections and business trends) are forward-looking statements. Rexahn s actual results may differ
More informationCalithera Biosciences. September 2018
Calithera Biosciences September 2018 Forward-Looking Statements This presentation and the accompanying oral commentary contain forward looking statements for purposes of the safe harbor provisions of the
More informationMERCK ONCOLOGY OVERVIEW AACR 2018 APRIL 16, 2018
MERCK ONCOLOGY OVERVIEW AACR 2018 APRIL 16, 2018 Forward-Looking Statement of Merck & Co., Inc., Kenilworth, NJ, USA This presentation of Merck & Co., Inc., Kenilworth, N.J., USA (the company ) includes
More informationCOMPANY OVERVIEW. June CytomX Therapeutics, Inc.
COMPANY OVERVIEW June 2016 2016 CytomX Therapeutics, Inc. Forward Looking Statements Special Note Regarding Forward-Looking Statements This presentation may contain projections and other forward-looking
More informationQ Financial Update November 6, 2018 NASDAQ:FPRX
Q3 2018 Financial Update November 6, 2018 NASDAQ:FPRX 2 Forward-Looking Statements Disclaimer Forward-looking statements contained in this presentation include statements regarding (i) the timing of initiation,
More informationImmunotherapy for the Treatment of Head and Neck Cancers. Robert F. Taylor, MD Aurora Health Care
Immunotherapy for the Treatment of Head and Neck Cancers Robert F. Taylor, MD Aurora Health Care Disclosures No relevant financial relationships to disclose I will be discussing non-fda approved indications
More informationBuilding a Leading Oncology Franchise
ASDAQ: MEIP Building a Leading Oncology Franchise 17th Annual eedham Healthcare Conference March 27, 2018 Forward-Looking Statements This presentation contains, and our officers and representatives may
More informationImmuno-Oncology Clinical Trials Update: Checkpoint Inhibitors Others (not Anti-PD-L1/PD-1) Issue 4 January 2017
Delivering a Competitive Intelligence Advantage Immuno-Oncology Clinical Trials Update: Checkpoint Inhibitors Others (not Anti-PD-L1/PD-1) Issue 4 January 2017 Immuno-Oncology CLINICAL TRIALS UPDATE The
More informationMerck Oncology Overview ASCO 2017
Merck Oncology Overview ASCO 217 June 5, 217 Forward-Looking Statement of Merck & Co., Inc., Kenilworth, NJ, USA This presentation of Merck & Co., Inc., Kenilworth, NJ, USA (the company ) includes forward-looking
More informationMerck Oncology Overview ASCO 2017
Merck Oncology Overview ASCO 217 June 5, 217 Forward-Looking Statement of Merck & Co., Inc., Kenilworth, NJ, USA This presentation of Merck & Co., Inc., Kenilworth, NJ, USA (the company ) includes forward-looking
More informationCowen Health Care Conference
Cowen Health Care Conference Dr. Fouad Namouni Head of Medical March 7, 2016 1 Forward-Looking Information This presentation contains statements about the Company s future plans and prospects that constitute
More informationA targeted oncology company developing a pipeline of cancer therapies for select patient populations.
A targeted oncology company developing a pipeline of cancer therapies for select patient populations. JEFFERIES GLOBAL HEALTHCARE CONFERENCE CHARLES BAUM, M.D., PH.D., PRESIDENT AND CEO JUNE 2015 Safe
More informationCorporate Presentation June Curis, Inc All Rights Reserved
Corporate Presentation June 2018 Curis, Inc. 2018 All Rights Reserved Forward Looking Statements This presentation contains certain forward-looking statements about Curis, Inc. ( we, us, or the Company
More informationCorporate Presentation May Transforming Immuno-Oncology Using Next-Generation Immune Cell Engagers
Corporate Presentation May 2016 Transforming Immuno-Oncology Using Next-Generation Immune Cell Engagers Forward-looking statements / safe harbor This presentation and the accompanying oral commentary contain
More informationAnnounce Expected Initiation of an Investigator-Initiated, Randomized, Phase 2, Multicenter Trial of Ficlatuzumab and Cetuximab in HNSCC in 2H 2017
AVEO Oncology and Biodesix Announce Results from Two Investigator-Sponsored Phase 1 Studies of HGF Targeted Antibody Ficlatuzumab at the 2017 ASCO Annual Meeting Announce Expected Initiation of an Investigator-Initiated,
More informationMerck KGaA, Darmstadt, Germany, and Pfizer to Present Avelumab Data in Seven Different Cancers at ASCO Annual Meeting
News Release Merck KGaA, Darmstadt, Germany Media: Gangolf Schrimpf +49 6151 72 9591 Investor Relations: +49 6151 72 3321 Pfizer Inc., New York, USA Media: Sally Beatty +1 212 733 6566 Investor Relations:
More information